ArticleCurrent pharmaceutical design2025
Investigation into the Mechanisms of Paeoniae Radix Rubra in the Treatment of Venous Thrombosis Using Network Pharmacology, Bioinformatics, and Molecular Docking Techniques.
Article in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stigmasterol reverses rituximab resistance in diffuse large B-cell lymphoma via the MAPK1 signaling pathway.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThis study investigates the potential targets and mechanisms of Paeoniae Radix Rubra (PRR) in treating Venous Thrombosis (VTE) by employing network pharmacology, bioinformatics analysis, and molecular docking validation.
methodsActive components of PRR were identified via TCMSP. VTE-related genes were screened from GEO datasets, and WGCNA analyzed key modules. A Protein-Protein Interaction (PPI) network was constructed using Cytoscape, followed by immune infiltration analysis. Core targets were functionally annotated via GO and KEGG pathways. Molecular docking and molecular dynamics simulations validated interactions between PRR components and core targets.
resultsA total of 30 active components of PRR and 21 potential targets for the treatment of VTE were identified. From the PPI network, 10 hub genes were screened. KEGG pathway enrichment analysis demonstrated that the target genes were significantly enriched in pathways, such as the cGMP-PKG signaling pathway, B cell receptor signaling pathway, Th1 and Th2 cell differentiation, and IL-17 signaling pathway. Molecular docking results revealed that MAPK1, NFATC1, and SELP all had good affinity with the screened active components. Among them, MAPK1 and beta-sitosterol exhibited the highest binding energy of -8.73 kcal/mol. Molecular dynamics simulation results from RMSD, RMSF, HBond, and SASA analyses indicated that the beta-sitosterol-MAPK1 complex maintained good stability.
conclusionThrough this study, it was found that PRR may act on targets, such as MAPK1 and NFATC1, through components like beta-sitosterol and Stigmasterol. Among them, the complex (beta-sitosterol - MAPK1) may be the key active component that plays a role in treating VTE.
Indexed as
Identifiers
40417754What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.